Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Optimizing Participation In Colorectal Cancer Screening By Direct Invitation Of Non Responders By General Practitionners (OPTIDEC COLO)

5 giugno 2026 aggiornato da: MSPU des 3 Provinces

Optimizing Participation In Colorectal Cancer Screening By Direct Invitation Of Non Responders By General Practitionners: A Randomized Controlled Cluster Trial

The goal of this randomized trial is to assess the effectiveness of a targeted telephone reminder strategy, implemented by the patient's general practitioner, in enhancing participation in colorectal cancer screening among individuals who are not up to date . The participants are patients between 50 to 74 years old as they are the target for colorectal cancer screening. The main questions are:

  • What is the percentage of patients who completed the colorectal cancer screening test during the intervention year , within the patient population of general practitioners participating in the study and identified as non-up-to-date for their screening status ?
  • Identifying potential factors influencing the effectiveness of the intervention based on various characteristics of the patient, the geographical area, the general practitioner, and the caller

Researchers will compare with other patients who are not up to date without the intervention of their general practionner with a telephone reminder.

Panoramica dello studio

Stato

Non ancora reclutamento

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

10000

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Franche-comté
      • Champlitte, Franche-comté, Francia
        • MSPU des 3 provinces
        • Investigatore principale:
          • José-Philippe MORENO, MD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

Sì

Descrizione

Inclusion Criteria for general practionners :

  • Practise in one of the four departments of the Franche-Comté region; ractise in a solo practice, group practice, multidisciplinary primary care centre , or community health centre;
  • Are engaged in general medical practice.
  • Have agreed to participate in the study.

Inclusion Criteria for patients :

  • patients within the practice population of general practitioners selected to participate in the study;
  • aged between 50 and 75 years inclusive;
  • affiliated with the French general health insurance scheme or the agricultural social insurance scheme

Exclusion Criteria for general practionners:

  • practise exclusively in a specialty other than general practice (e.g. osteopathy, allergology, vascular medicine).

Non inclusion Criteria for patients :

- Objection expressed by the patient to the change in the purpose of data processing for research purposes

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Selezione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Intervention Arm : phone-based outreach to promote colorectal cancer screening
In year n, the 50 selected general practitioners will receive from the national health insurance a list of patients who are not up to date with colorectal cancer screening. Each patient's screening status will be verified by the clinical research associate through a review of the medical records. A telephone call will be made by a member of the patient's primary care team.
A telephone call will be made by a member of the patient's primary care team (general practitioner, medical secretary, public health nurse, or care coordinator), with priority given to a call by the patient's general practitioner. The call should preferably be made to the patient's mobile phone. If the call is unsuccessful, a voicemail message will be left, and a second call will be attempted within the following seven days. The voicemail message will include the name of the patient's general practitioner, the purpose of the call regarding colorectal cancer screening, and notification that a further attempt will be made to reach the patient. If the telephone exchange is successful, an appointment at the healthcare facility will be offered to the patient, during which the screening test will be offered to the patient, during which the screening test will be handed over and explained by one of the healthcare professionals from the same facility.
Nessun intervento: Control arm
In year n, the 50 selected general practitioners will receive from the national health insurance a list of patients who are not up to date with colorectal cancer screening. Each patient's screening status will be verified by the clinical research associate through a review of the medical records. There will not be an intervention.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of patients who completed the colorectal cancer screening in each arms
Lasso di tempo: 6 months after inclusion

Patients who completed the colorectal cancer screening test during the intervention year (year n), within the patient population of general practitioners participating in the study, and who were identified from the national health insurance list as not up to date with screening - a status that was confirmed by reviewing their medical records.

Completion of the screening will be confirmed by the presence of the test result in the patient's medical record within the General practionner's practice software, no later than three months after the end of the intervention.

This mesure will be done in each arm.

6 months after inclusion

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of patients whose colorectal cancer screening status was updated according to the National Health Insurance database
Lasso di tempo: 1 year after enrollment

Patients whose colorectal cancer screening status changed between the list received from National Health in year n and the list received in year n+1.

A change in status will be confirmed by the absence of the patient from the n+1 list, among those still registered within the general practitioner's patient panel.

1 year after enrollment
Number of patients who completed the colorectal cancer screening in the intervention arm according differents variables
Lasso di tempo: 3 months after the end of enrollment

Patients who completed the colorectal cancer screening (CRC) test during the intervention year , within the patient population of general practitioners participating in the study, and who were identified from the national health insurance list as not up to date with screening. This proportion will be analysed according to the following stratification variables:

  • Patient-related variables: age, sex
  • Territorial variables: level of urbanisation, deprivation index, participation rate in CRC screening in 2023
  • General practionner-related variables: age, sex, solo vs group practice
  • Caller status: profession of the person who made the call
3 months after the end of enrollment
Number of participants per stage of the intervention process
Lasso di tempo: 3 months after the end of enrollment

In both study arms, identification of patients incorrectly included in the national health insurance list (i.e. patients already up to date with screening, those excluded from CRC screening, those under or awaiting colonoscopic follow-up, or currently undergoing treatment for colorectal cancer).

For the intervention arm, classification of all patients according to the following outcomes:

  • Patients contacted
  • Patients who refused screening
  • Patients who accepted to participate
  • Patients who attended the healthcare facility to collect the screening kit
  • Patients for whom the test result was received by the general practitioner
3 months after the end of enrollment
quantifying the time required to carry out the intervention
Lasso di tempo: 3 months after the end of the enrollment

In the intervention arm, time spent on all stages of the intervention:

  • Processing the Assurance Maladie list
  • Making telephone calls
  • Patient follow-up
3 months after the end of the enrollment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 marzo 2028

Date di iscrizione allo studio

Primo inviato

29 giugno 2025

Primo inviato che soddisfa i criteri di controllo qualità

5 giugno 2026

Primo Inserito (Effettivo)

10 giugno 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 giugno 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

5 giugno 2026

Ultimo verificato

1 giugno 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 2025-A01370-49

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi